New drug nearly doubles survival rates in some pancreatic cancer patients, study says An experimental drug, daraxonrasib, has demonstrated a significant advancement in treating advanced pancreatic cancer by nearly doubling overall survival rates in a recent study. The drug targets a mutated protein crucial for tumor growth and reduced the risk of death by 60% in previously treated patients compared to standard chemotherapy. While not a cure, the medication offers a substantial benefit, with patients experiencing longer survival times, fewer severe side effects, and improved quality of life.

• Daraxonrasib, an experimental drug, nearly doubled overall survival rates for patients with advanced pancreatic cancer.
• The drug targets a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases.
• Patients taking daraxonrasib lived for a median of 13.2 months compared to 6.7 months for those receiving chemotherapy.
• The medication reduced the risk of death by 60% for previously treated metastatic pancreatic cancer patients.
• Patients experienced fewer severe side effects, less pain, and a better quality of life.
• The Food and Drug Administration plans to expedite its review of daraxonrasib.
• Former U.S. Sen. Ben Sasse reported a significant reduction in tumor volume and pain after taking the drug.